The stock of Invacare Corporation (NYSE:IVC) has been Initiated to Buy by Needham in its latest research note that was published on January 24. IVC was given a price target of $15, with other Wall Street analysts also giving their reports regarding the stock. KeyBanc Capital Mkts analysts have downgraded their rating of IVC stock from Overweight to Sector Weight in a separate flash note to investors on August 16
Invacare’s stock is covered by 5 analysts, with 1 of them rating the stock as Buy. It has been deemed to have strong buy by 2 of the analysts, 2 of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only 1 analysts. 2 of them rated it as strong buy with 2 of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that IVC has an average analyst rating of 2.20.
Invacare Corporation, which has current market capitalization of above $192 Million, published its last quarter earnings on June 30, 2019. The company was able to amass $223.42 million in revenue. This figure is $6.51 million more than what analysts had expected which was $229.93 million. During the first quarter of the year, Invacare also recorded $-0.32 earnings per share (EPS) which is $0.01 above the $-0.33 estimated by Thomson Reuter’s analyst, leading to a surprise factor of -1.84%.
IVC surged by $0.11 during the normal trading session on Tuesday and reaching a high of $5.98 during the day while it closed the day at $5.67. The Invacare stock had a low trading volume of 0.27 million shares on that day, which is low compared to the average daily volume of 371.90M shares. IVC has also gained 0.89% of its value over the past 7 days. However, the stock has declined by 16.62% in the 3 months of the year. Over the past six months meanwhile, it has gained 8.41% while it has added 31.86% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -21.03% from its 3 months high price. However, taking another look at IVC will indicate that it is trading +37.29% away from its 90-day low. Looking at the bigger picture, the Invacare Corporation stock has dropped by -65.84% from its 52-week high while it has surged by +85.9% from its 52-week low price.
On November 20, 2018 Leneghan Kathleen P., Senior VP and CFO bought 6500 shares of the company. The average price for that transaction was $5.52 per share, which meant that Leneghan Kathleen P. spent $35880 purchasing the stocks. The purchase was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Director, NASTAS CLIFFORD D purchasing 9000 shares of this stock on November 19, 2018. The average purchasing price for the stock was $5.42 per share, with the purchased stock accruing $48780. Following this transaction, the Director NASTAS CLIFFORD D now holds 243897 shares of the company, which is worth around $1431675.
Invacare has around 90 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $194 Billion. The Invacare stock is bringing in revenue of over 12 months, which is roughly 171 Billion. Despite all that, Invacare Corporation is seeing things declining very much as their y-o-y quarterly revenue dropped by -4.48%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 72.64%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 74.76%. Over the past 20 days, Invacare’s Stochastic %K stood at 81.88% while its Stochastic %D was revealed to be 84.92%.